Emergent Biosolutions Share Holder Equity 2010-2022 | EBS

Emergent Biosolutions share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Emergent Biosolutions Annual Share Holder Equity
(Millions of US $)
2021 $1,619
2020 $1,447
2019 $1,089
2018 $1,011
2017 $912
2016 $596
2015 $660
2014 $553
2013 $489
2012 $442
2011 $417
2010 $374
2009 $244
Emergent Biosolutions Quarterly Share Holder Equity
(Millions of US $)
2022-06-30 $1,513
2022-03-31 $1,575
2021-12-31 $1,619
2021-09-30 $1,523
2021-06-30 $1,544
2021-03-31 $1,523
2020-12-31 $1,447
2020-09-30 $1,252
2020-06-30 $1,199
2020-03-31 $1,075
2019-12-31 $1,089
2019-09-30 $1,035
2019-06-30 $989
2019-03-31 $988
2018-12-31 $1,011
2018-09-30 $967
2018-06-30 $938
2018-03-31 $881
2017-12-31 $912
2017-09-30 $664
2017-06-30 $621
2017-03-31 $610
2016-12-31 $596
2016-09-30 $548
2016-06-30 $673
2016-03-31 $667
2015-12-31 $660
2015-09-30 $605
2015-06-30 $562
2015-03-31 $538
2014-12-31 $553
2014-09-30 $513
2014-06-30 $488
2014-03-31 $477
2013-12-31 $489
2013-09-30 $467
2013-06-30 $449
2013-03-31 $436
2012-12-31 $442
2012-09-30 $428
2012-06-30 $423
2012-03-31 $412
2011-12-31 $417
2011-09-30 $385
2011-06-30 $381
2011-03-31 $359
2010-12-31 $374
2010-09-30 $279
2010-06-30 $262
2010-03-31 $249
2009-12-31 $244
2009-09-30 $237
2009-06-30 $230
2009-03-31 $213
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.040B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00